The Board of Directors of SciBase resolves on a previously communicated rights issue of shares of approximately SEK 83 million

SciBase's board has resolved a rights issue to raise approximately SEK 83 million at SEK 0.20 per new share (one subscription right per existing share), with the subscription period running 12–26 January 2026 and record date 8 January 2026. The issue is covered by subscription commitments of roughly SEK 64.3 million (77.6%) and includes additional undertakings from Castle Bioscience and Haga Gruppen; transaction costs are estimated at SEK 3.4 million. Proceeds are earmarked to fund US commercialization and expansion in nearby European markets and are expected to finance the company well into 2027; full subscription would issue up to 414,182,643 new shares (50% dilution) and, combined with a fully exercised TO2 warrant offering, total dilution could reach ~61.6%. The release notes Germany generates >SEK 20m annual revenues with over 400 systems installed and US revenues grew >200% in the first nine months of 2025, while break-even is targeted at an installed base of 800–1,000 systems with 5–7 electrodes/week utilization.

Analysis

Market structure: SciBase gains immediate liquidity (~SEK 83m gross) to fund US commercialization through 2027; winners include recurring-electrode revenue stream and Castle Bioscience (CSTL) as manufacturing/customer partner. Losers: existing SciBase shareholders face up to 50% dilution (61.6% if TO2 accepted) and potential downward pressure on the share price until proof of US unit utilization (target 800–1,000 systems; 5–7 electrodes/week). Competitive dynamics favor vendors with installed-system + consumables models; pricing power depends on demonstrated clinical ROI and reimbursement in the US.

Risk assessment: Tail risks include ISP FDI blocking large non-Swedish stakes, failure to hit US utilization (operational), and undersubscription (only ~77.6% committed today) causing a cash shortfall. Immediate (days): ex-rights price shock around Jan 7–12; short-term (weeks–months): subscription outcome by Jan 27 and TO2 acceptance by Jan 8; long-term (quarters): break-even only if installed base reaches 800–1,000 with stable electrode usage into 2027. Hidden dependencies: Castle’s conditional SEK 23m extra subscription (capped at <20% ownership) and TO2 conversions materially change capital structure and incentives.

Trade implications: If you can participate, buying subscription rights (12–21 Jan) and subscribing at SEK 0.20 preserves value; otherwise expect ~30–50% mechanical dilution drag on market cap post-issue. Relative trade: long CSTL (partnership beneficiary) vs short SciBase equity around ex-rights to capture differential operational vs financing risk. Options: prefer calendar call spreads or protective puts around key dates (subscription close Jan 26, outcome Jan 27). Catalysts: US reimbursement news, quarterly US installation data, TO2 uptake, and ISP FDI decisions.

Contrarian angles: Consensus focuses on dilution while underweighting recurring consumable margins and fast US revenue growth (>200% YTD) that can re-rate valuation if utilization scales. Mispricing risk: market may over-discount proceeds — if SciBase hits 50%+ of target installed base by end-2026, upside could be multiple turns from low base. Unintended consequence: FDI notification friction could deter strategic buyers, keeping the stock cheap longer; watch TO2 acceptance which could push dilution to >60% and materially change the thesis.

Key Decisions for Investors

• If eligible, acquire SciBase subscription rights between 12–21 Jan and subscribe at SEK 0.20 to maintain pro-rata exposure; size 1–3% NAV, target 2x return within 12–18 months if US installed base growth sustains, stop-loss at -35% from entry.
• Establish a tactical short SciBase equity position (size 1–2% NAV) into ex-rights (7 Jan) to capture expected mechanical dilution and execution premium; cover or reassess after the outcome announcement on 27 Jan or if subscription coverage >95%.
• Initiate a 1–2% long position in CSTL (Castle Bioscience) to capture partnership upside (manufacturing/recurring demand), monitor Castle’s conditional SEK 23m commitment and its post-issue ownership; take profits if Castle’s stake approaches 20% (FDI/ownership risk).
• If liquid options exist, buy 6–12 month SciBase call spreads (buy 12-month ATM/20% OTM call, sell 12-month +40% OTM) sized to 0.5–1% NAV if the Rights Issue is fully subscribed; alternatively buy 2–3 month puts expiring Mar 2026 OTM ~20% as a cheap hedge against under-subscription/US adoption miss.